{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-004977","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2026-07-29T11:20:33+00:00","discovered_at":"2026-07-29T11:25:00.257670+00:00","generated_at":"2026-07-29T11:25:10.098506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Anika Q2 revenue $32.6M (+16% YoY); raises FY 2026 guidance, adj. EBITDA margin 13-17%","bullets":["Q2 revenue $32.6M, up 16% YoY; Commercial Channel record $13.9M (+17%); OEM $18.7M (+14%).","Gross margin 65%; net income $3.3M ($0.24 diluted EPS); adjusted EBITDA $7.1M (22% margin).","Raising FY 2026 guidance: total revenue growth 5-10% (prev 1-9%); adj. EBITDA margin 13-17% (prev 5-10%).","Revised 2027 Commercial revenue growth 5-15% (prev 10-20%); total company flat to 5% growth.","International revenue record $12.6M (+22% YoY); Integrity units up 39% YTD; Hyalofast/Cingal progress."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-004977","json":"https://secwatch.observer/filing/0001171843-26-004977.json","markdown":"https://secwatch.observer/filing/0001171843-26-004977.md","text":"https://secwatch.observer/filing/0001171843-26-004977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184326004977/0001171843-26-004977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184326004977/f8k_072926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T11:25:10.098506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}